ORGANOVO HOLDINGS INC (ONVO)

US68620A2033 - Common Stock

0.448  +0.01 (+1.73%)

Fundamental Rating

2

Taking everything into account, ONVO scores 2 out of 10 in our fundamental rating. ONVO was compared to 571 industry peers in the Biotechnology industry. ONVO scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ONVO does not seem to be growing, but still is valued expensively.



0

1. Profitability

1.1 Basic Checks

In the past year ONVO has reported negative net income.
ONVO had a negative operating cash flow in the past year.
ONVO had negative earnings in each of the past 5 years.
ONVO had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

Looking at the Return On Assets, with a value of -147.66%, ONVO is doing worse than 84.83% of the companies in the same industry.
The Return On Equity of ONVO (-209.89%) is worse than 68.96% of its industry peers.
Industry RankSector Rank
ROA -147.66%
ROE -209.89%
ROIC N/A
ROA(3y)-116.81%
ROA(5y)-91.68%
ROE(3y)-185.97%
ROE(5y)-134.22%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ONVO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

6

2. Health

2.1 Basic Checks

ONVO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ONVO has more shares outstanding
The number of shares outstanding for ONVO has been increased compared to 5 years ago.
ONVO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

ONVO has an Altman-Z score of -53.57. This is a bad value and indicates that ONVO is not financially healthy and even has some risk of bankruptcy.
ONVO's Altman-Z score of -53.57 is on the low side compared to the rest of the industry. ONVO is outperformed by 94.53% of its industry peers.
There is no outstanding debt for ONVO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -53.57
ROIC/WACCN/A
WACC10.31%

2.3 Liquidity

A Current Ratio of 3.58 indicates that ONVO has no problem at all paying its short term obligations.
The Current ratio of ONVO (3.58) is comparable to the rest of the industry.
ONVO has a Quick Ratio of 3.38. This indicates that ONVO is financially healthy and has no problem in meeting its short term obligations.
ONVO has a Quick ratio (3.38) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 3.58
Quick Ratio 3.38

1

3. Growth

3.1 Past

ONVO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 15.57%, which is quite good.
The Revenue for ONVO has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)15.57%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%69.57%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 10.35% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3Y8.61%
EPS Next 5Y10.35%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ONVO. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3Y8.61%

0

5. Dividend

5.1 Amount

No dividends for ONVO!.
Industry RankSector Rank
Dividend Yield N/A

ORGANOVO HOLDINGS INC

NASDAQ:ONVO (11/29/2024, 12:29:07 PM)

0.448

+0.01 (+1.73%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap6.89M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -147.66%
ROE -209.89%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM N/A
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 3.58
Quick Ratio 3.38
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)15.57%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next YN/A
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y